|
|
 |
|
Viewing report
|
|
|
|
Nanotechnology: Players, products & prospects to 2018 (Volume II)
Espicom Business Intelligence Ltd, June 2009, Pages: 106
Nano-enabled Delivery
The true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It has been successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on the topic and established Task Forces to monitor the progress and application of this technology although there are presently no regulations specific to nanomedicine or nano-enabled medical devices.
As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industry’s need for therapeutic, bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data with novel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancer therapies.
The potential of future applications:
Tissue specific delivery - targeting the delivery of small and macro molecules across biological membranes such as the blood brain barrier for CNS drugs;
Gene and vaccine delivery - non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiency and expression;
Controlled-release devices - design of new nanoporous, bioerodible membranes;
Increased biocompatibility - design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatory response;
Improved drug bioavailability and solubility - through the engineering of drugs and reagents by nanostructuring;
Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs.
By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketed nano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of high unmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious than first generation products.
By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as an important tool in the industry’s delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.
This report is part of a major new 4-volume strategic analysis
Drug Delivery Technologies:
Players, Products & Prospects to 2018
Focusing on the sectors that are driving growth
VOLUME I
CONTROLLED- RELEASE
VOLUME II
NANOTECHNOLOGY
VOLUME III
NUCLEIC ACID DELIVERY
VOLUME IV
TARGETED DELIVERY
Customers who bought this item also bought
Nanoparticle Drug Delivery Market Report
Controlled-release: Players, products & prospects to 2018 (Volume I)
Medical Nanotechnology Market Guide 2012
Emerging Opportunities in Cancer Nanomedicine
Medical Nanotechnology: Industry Overview and Potential
Drug Solubility Technology and Platforms: Evolving Strategies, Emerging Opportunities
Targeted Drug Delivery Analysis
Medical Nanotechnology Markets
Nanotechnology in Healthcare: Market Outlook for Applications, Tools and Materials and 40 Company Profiles
Drug Delivery Systems: US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
|
|
|
